Oramed Pharmaceuticals (ORMP) EBIT (2011 - 2026)

Oramed Pharmaceuticals has reported EBIT for 15 years, with the latest figure at -$3.7 million in Q1 2026.

• For the quarter ending Q1 2026, EBIT rose 18.69% year-over-year to -$3.7 million; the trailing twelve-month figure through Mar 2026 stood at $16.7 million (up 441.3% YoY), and the FY2025 full-year result was $15.8 million, up 573.17% from the prior year.
• EBIT for Q1 2026 stood at -$3.7 million, down from $25.2 million in the prior quarter.
• The five-year high for EBIT was $25.2 million in Q4 2025, with the low at -$12.3 million in Q4 2022.
• Historically, EBIT has averaged -$2.0 million across 5 years, with a median of -$3.1 million in 2024.
• Annual changes were most pronounced in 2024 — EBIT tumbled 54.92% — and 2025, when it soared 331.87%.
• Oramed Pharmaceuticals' EBIT stood at -$12.3 million in 2022, then soared by 205.14% to $13.0 million in 2023, then plunged by 54.92% to $5.8 million in 2024, then soared by 331.87% to $25.2 million in 2025, then tumbled by 114.5% to -$3.7 million in 2026.
• The last three EBIT figures came in at -$3.7 million (Q1 2026), $25.2 million (Q4 2025), and -$2.4 million (Q3 2025), per Business Quant data.